Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $43.4100 (-4.8%) ($43.4100 - $43.4100) on Mon. Mar. 29, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.45% (three month average) | RSI | 49 | Latest Price | $43.4100(-4.8%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.9% a day on average for past five trading days. | Weekly Trend | TGTX declines -2.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(67%) ARKG(64%) ARKK(59%) IWO(59%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.725% in a week (0% probabilities). VIXM(-41%) VXX(-36%) UUP(-18%) UNG(-3%) IGOV(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.725% (StdDev 3.45%) | Hourly BBV | -1.1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $46.28 | 5 Day Moving Average | $45.88(-5.38%) | 10 Day Moving Average | $46.93(-7.5%) | 20 Day Moving Average | $46.28(-6.2%) | To recent high | -19.8% | To recent low | 4.2% | Market Cap | $5.498b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |